Sovremennyy vzglyad na problemu farmakoterapii ANTsA-assotsiirovannykh sistemnykh vaskulitov


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

ANCA-associated systemic vasculitis is an urgent problem of clinical medicine due to the difficulty in diagnosing the disease onset, multisystemic lesions and a high risk of disability. Necrotizing inflammation of small vessels determines the severity of lesions in ANCA-associated vasculitides and creates difficulties of differential diagnosis. The article presents the results of own authors’ clinical research and international randomized trials regarding clinical course and the effectiveness of the main pathogenetic agents for the treatment of ANCA-associated systemic vasculitides.

Full Text

Restricted Access

References

  1. Насонов Е.Л. Ревматология: клинические рекомендации. М., 2011. 752 с.
  2. Мазуров В.И., Беляева И.Б., Зоткин Е.Г. Диффузные заболевания соединительной ткани. М., 2011. С. 172.
  3. Eisenberger U., Hess C. Systemic ANCA-associated vasculitis - diagnosis and therapy. Ther. Umsch. 2008; 65(5): 295-301.
  4. Mahr A., Guillevin L. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004; 51: 92-9.
  5. Насонов Е.Л., Баранов А.А., Шилкина Н.П. Васкулиты и васкулопатии. Ярославль, 1999. С. 340-47.
  6. Richard A. Watts, David G.I. Scott. Vasculitis in Clinical Practice Springer-Verlag N.Y., 2010. P. 71-7.
  7. Groot K., Harper L., Jayne D., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. A randomized trial. Ann Intern. Med. 2009; 150: 670-80.
  8. Mukhtyar C., Guillevin L., et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum. Dis. 2009; 68: 310-17.
  9. Pagnoux C., Mahr A., Hamidou M., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 2008; 359: 2790-803.
  10. De Groot K., Rasmussen N., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005; 52: 2461-69.
  11. Cartin-Ceba R., Keogh K., et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011; 26: 2865-71.
  12. Guerry M.-J., Brogan P., et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology. 2012; 51: 634-43.
  13. Бекетова Т.В. Перспективы применения Ритуксимаба при васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами. Научнопрактическая ревматология. 201 0; 4 (приложение 1): 80-90.
  14. Silva-Fernandez L., Loza E., Martinez-Taboada V.M., et al. Biological therapy for systemic vasculitis: A systematic review. Semin Arth Rheum. 2014; 43(4): 542-57.
  15. Stegeman C.A., Tervaert J.W., Sluiter W.J., et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994; 120(1): 12-7.
  16. Metzler C., Miehle N., Manger K., et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007; 46: 1087-91.
  17. Hazlewood G.S., Metzler C. Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis. Joint Bone Spine. 2014; 81(4): 337-41.
  18. Hiemstra T., Walsh M., Schmitt W., Jayne D. Randomised controlled trial of mycophenolate mofetil versus azathioprine for maintenance therapy in ANCA-Associated vasculitis (IMPROVE). 1-4th Nov American Society of Nephrology 2009: SA-FC331A.
  19. Jayne D.R., Gaskin G., et al. European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 2007; 18(7): 2180-88.
  20. Rona M. Smith, Rachel B. Jones and David RW Jayne. Progress in treatment of ANCA-associated vasculitis. Arthritis Res. Ther. 2012; 14: 210.
  21. Jayne D., Chapel H., Adu D., et al. Intravenous immunoglobulin for ANCA- associated systemic vasculitis with persistent disease activity. Q J Med. 2000; 93: 433-39.
  22. De Menthon, M., Cohen, P., et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin. Exp. Rheumatol. 2011; 29: 63-71.
  23. Morgan M.D., Drayson M., et al. Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin. Pract.2010; 117: 89-97.
  24. Laurino S., Chaudhry A., et al. Prospective study of TNF-alpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol. Dial. Transplant. 2010; 25: 3307-14.
  25. Stone J.H., Holbrook J.T., et al. Wegener's Granulomatosis Etanercept Trial Research Group: Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006; 54: 1608-18.
  26. Moosig F., Gross W.L., et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Internal. Med. 2011; 155: 341-43.
  27. Walsh M., Chaudhry A., et al. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum. Dis. 2008; 67: 1322-27.
  28. Flossmann O., Jayne D.R., et al. Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. Rheumatology (Oxford). 2010; 49: 556-62.
  29. Schmitt W.H., Hagen E.C., et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004; 65: 1440-48.
  30. Krumbholz M., Specks U., et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J. Autoimmun. 2005; 25: 298-302.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies